|
[Related PubMed/MEDLINE] Total Number of Papers: 53
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2020 |
A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. |
AUC, PK |
2 |
2020 |
Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. |
D-Rd, DLT, NDMM |
3 |
2020 |
Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. |
--- |
4 |
2020 |
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. |
ACR20, ADA, ADAb, ETN, INF, ISRs, RA |
5 |
2020 |
Implementation and Evaluation of a 90-Minute Rituximab Infusion Protocol at the Richard L. Roudebush VA Medical Center. |
HCPs, RLRVAMC |
6 |
2020 |
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. |
ALL, CNS, TDM |
7 |
2020 |
Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period? |
NTZ |
8 |
2020 |
Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. |
OCR |
9 |
2020 |
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. |
mAb, PD |
10 |
2020 |
Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. |
AIHA, CLL |
11 |
2020 |
Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol. |
--- |
12 |
2020 |
Safety of ninety-minute daratumumab infusion. |
--- |
13 |
2020 |
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. |
--- |
14 |
2020 |
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. |
MS |
15 |
2020 |
The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease. |
alpha-Gal A, ERT, FD |
16 |
2019 |
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer. |
CI |
17 |
2019 |
Incidence and Management of Olaratumab Infusion-Related Reactions. |
anti-alpha-Gal |
18 |
2019 |
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. |
COO, DLBCL, SDI |
19 |
2019 |
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. |
MS, PPMS, RMS, s.c |
20 |
2019 |
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. |
MPM |
21 |
2019 |
The importance of early identification of infusion-related reactions to monoclonal antibodies. |
--- |
22 |
2018 |
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. |
MM |
23 |
2018 |
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. |
ASCT, BV, CR, HL |
24 |
2018 |
Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis. |
CLL, CR, PALG, PFS, PR |
25 |
2018 |
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. |
AEs, ASCT, BV, HL, NIVO, R/R |
26 |
2018 |
Safety of shortened infusion times for combined ipilimumab and nivolumab. |
--- |
27 |
2018 |
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. |
AEs, irAEs, MedDRA, PD-L1, TRAEs |
28 |
2018 |
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. |
--- |
29 |
2017 |
A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. |
B-NHL, OR |
30 |
2017 |
An update on the role of daratumumab in the treatment of multiple myeloma. |
DARA, mAbs, MM |
31 |
2017 |
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. |
OS |
32 |
2017 |
Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma. |
AEs, iNHL, OS, PFS |
33 |
2017 |
Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients. |
--- |
34 |
2016 |
A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. |
PK |
35 |
2016 |
Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab. |
CLL |
36 |
2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. |
IgG1kappa, MM, RP2D |
37 |
2015 |
Clinical development methodology for infusion-related reactions with monoclonal antibodies. |
mAbs |
38 |
2015 |
Prevention and management of obinutuzumab-associated toxicities: Australian experience. |
CLL |
39 |
2015 |
Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. |
CLL |
40 |
2015 |
Safety of Infusing Ipilimumab Over 30 Minutes. |
--- |
41 |
2014 |
Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. |
--- |
42 |
2014 |
Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. |
DLBCL, FL |
43 |
2014 |
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. |
RA |
44 |
2014 |
The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. |
--- |
45 |
2013 |
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. |
--- |
46 |
2013 |
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. |
DLBCL, MCL |
47 |
2013 |
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). |
AE, CR |
48 |
2013 |
Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. |
AmB |
49 |
2012 |
Optimizing premedications in the prevention of bendamustine infusion-related reactions. |
CLL, FN |
50 |
2011 |
Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). |
ERT, HOS, MPS II |
51 |
2010 |
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. |
mCRC, OS, PFS |
52 |
2008 |
Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. |
ABCD |
53 |
2005 |
Tolerability and safety of rituximab (MabThera). |
RA |
|